Literature DB >> 22846778

Myopic maculopathy: a review.

Rufino Silva1.   

Abstract

Pathological myopia is a major cause of irreversible vision loss and is the fourth to ninth most frequent cause of blindness in the world. Choroidal neovascularization (CNV) secondary to pathological myopia is the leading cause of vision impairment in patients younger than 50 years. New scientific contributions have been made to the understanding of high myopia and associated CNV. New treatments have been used in recent years, and the results are still controversial. This paper is an updated review of pathological myopia--its definition and progression, epidemiology and genetics--and a review of myopic CNV including the natural history, epidemiology, risk factors, pathogenic mechanisms and treatment.
Copyright © 2012 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2012        PMID: 22846778     DOI: 10.1159/000339893

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  21 in total

1.  Prevalence and Characteristics of Myopic Degeneration in an Adult Chinese American Population: The Chinese American Eye Study.

Authors:  Farzana Choudhury; Stacy M Meuer; Ronald Klein; Dandan Wang; Mina Torres; Xuejuan Jiang; Roberta McKean-Cowdin; Rohit Varma
Journal:  Am J Ophthalmol       Date:  2017-12-27       Impact factor: 5.258

2.  Therapeutic effect of intravitreal injections of ranibizumab for the treatment of macular choroidal neovascularization caused by pathological myopia.

Authors:  Leibing Ji; Wenjuan Lv; Yun Xiao; Zhenghua Xu; Xiaoling Zhang; Wei Zhang
Journal:  Exp Ther Med       Date:  2015-07-07       Impact factor: 2.447

Review 3.  Current and emerging treatment options for myopic choroidal neovascularization.

Authors:  Leila El Matri; Ahmed Chebil; Fedra Kort
Journal:  Clin Ophthalmol       Date:  2015-04-24

4.  Foxg1-Cre Mediated Lrp2 Inactivation in the Developing Mouse Neural Retina, Ciliary and Retinal Pigment Epithelia Models Congenital High Myopia.

Authors:  Olivier Cases; Antoine Joseph; Antoine Obry; Mathieu D Santin; Sirine Ben-Yacoub; Michel Pâques; Sabine Amsellem-Levera; Ana Bribian; Manuel Simonutti; Sébastien Augustin; Thomas Debeir; José Alain Sahel; Annabel Christ; Fernando de Castro; Stéphane Lehéricy; Pascal Cosette; Renata Kozyraki
Journal:  PLoS One       Date:  2015-06-24       Impact factor: 3.240

Review 5.  Anti-VEGF treatment for myopic choroid neovascularization: from molecular characterization to update on clinical application.

Authors:  Yan Zhang; Qian Han; Yusha Ru; Qiyu Bo; Rui Hua Wei
Journal:  Drug Des Devel Ther       Date:  2015-07-02       Impact factor: 4.162

6.  Prevalence of blindness and causes of visual impairment among adults aged 50 years or above in southern. Jiangsu Province of China.

Authors:  Yong Yao; Jun Shao; Wei Sun; Jing Zhu; Dong Hong Fu; Huaijing Guan; Qinghuai Liu
Journal:  Pak J Med Sci       Date:  2013-09       Impact factor: 1.088

7.  NYX mutations in four families with high myopia with or without CSNB1.

Authors:  Lin Zhou; Tuo Li; Xiusheng Song; Yin Li; Hongyan Li; Handong Dan
Journal:  Mol Vis       Date:  2015-03-05       Impact factor: 2.367

Review 8.  Myopic choroidal neovascularisation: current concepts and update on clinical management.

Authors:  Tien Y Wong; Kyoko Ohno-Matsui; Nicolas Leveziel; Frank G Holz; Timothy Y Lai; Hyeong Gon Yu; Paolo Lanzetta; Youxin Chen; Adnan Tufail
Journal:  Br J Ophthalmol       Date:  2014-07-01       Impact factor: 4.638

Review 9.  Anti-VEGF Therapy and the Retina: An Update.

Authors:  Vikas Tah; Harry O Orlans; Jonathan Hyer; Edward Casswell; Nizar Din; Vishnu Sri Shanmuganathan; Louise Ramskold; Saruban Pasu
Journal:  J Ophthalmol       Date:  2015-08-31       Impact factor: 1.909

10.  Ranibizumab, verteporfin photodynamic therapy or observation for the treatment of myopic choroidal neovascularization: cost effectiveness in the UK.

Authors:  Lindsay Claxton; Bill Malcolm; Matthew Taylor; Jennifer Haig; Claudia Leteneux
Journal:  Drugs Aging       Date:  2014-11       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.